ERBB2 and breast cancer: Similar findings have also been reported in studies across other breast cancer subtypes, where a reduction in IHC-Ki67 following neoadjuvant chemotherapy, anti-HER2 therapy, and endocrine treatment has been associated with a better prognosis [[36], [37], [38]].